Pharmaceutical

As the pioneer in laser drilling, Lenox Laser takes pride in the various services that we provide to our customers. In light of the COVID-19 pandemic, the importance of Container Closure Integrity Testing (CCIT) has become abundantly clear. Confidence in pharmaceutical packaging is vital to prevent widespread damage caused by the failure of critical seals. Lenox Laser assists in this process by producing standards that calibrate leak-detection systems in order to assure the quality and safety of the packaging.

By utilizing lasers, Lenox drills precise, microscopic imperfections in a wide variety of packaging. Our systems are capable of drilling metals and alloys, glass, plastics, and more. We can accommodate custom materials and requirements upon request. All orifices drilled for CCIT are calibrated to NIST secondary standards using our proprietary flow calibration processes, ensuring precise measurements. Recalibration services are also available to ensure the accuracy of previously drilled parts. Our standard products are optically measured, but when a greater level of accuracy is required, Lenox Laser can drill orifices to produce a specific flow rate for custom applications. Calculate a custom orifice diameter based on your specifications with our orifice calculator.

On top of CCIT, Lenox Laser provides other services such as laser machining, laser engraving, and more. Lenox Laser also offers standard products for optical and flow applications. For any questions you have about our capabilities, please contact us.

We thank our customers for their continued support over the past 40 years. It is with your help that Lenox Laser continues pioneering in the small-hole industry.

              With the vaccine for Covid-19 arriving late last year, people are now starting to see a glimmer of hope for the future. The challenge now is keeping up with demand in several markets because there are currently shortages. According to a report recently released by the Washington Post, as of the time writing this, approximately 20.3 million people have received doses of the vaccine. However, all over the world, vaccine distribution is moving at a desperately slow pace. This is what started the idea of using multi-product facilities to speed up the production and distribution of the vaccine as quickly and safely as possible. The first step to this needing to be conquered is updating outdated facilities and equipment. Grand River Aseptic Manufacturing (GRAM), a contract-based manufacturer of sterile injectable drugs based out of Grand Rapids, Michigan, is stepping up to aid in this goal.

              One of the significant parts of this initiative is to create massive facilities that are top-of-the-line with the most advanced equipment possible, bringing these facilities into a new era of prosperity. When the virus started, it has been a massive time crunch ever since to get to where we are today. Billions of dollars have been spent on creating and distributing this vaccine. Having updated facilities and converting as many areas as possible to allow it, GRAM believes, could reduce costs and spare precious time. The company is investing in other businesses to bring this innovation to them.

              GRAM will invest in equipment to prevent cross-contamination and improve safety and health protocols and flexibility for all parties involved. As the world’s current state has been in, it is a true marvel to see just how far the medical community has come with innovations, technology, and sustainability.

If you would like to read more about the future of the pharmaceutical industry, please click here.